21 results on '"Wolden S"'
Search Results
2. Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).
3. Phase II window of irinotecan plus carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099.
4. Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis
5. Whole neuraxis irradiation to address central nervous system (CNS) relapse in high-risk neuroblastoma (NB)
6. Metastatic neuroblastoma (NB) to the central nervous system (CNS): Improved outcome with combined modality including 131-I-8H9 or 131-I-3F8 radioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF)
7. Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better
8. Long-term complications of neuroblastoma: A report from the Childhood Cancer Survivor Study
9. Intensity-modulated radiation therapy for head and neck cancer of unknown primary
10. Preliminary results of concurrent chemotherapy with intensity-modulated radiation therapy (IMRT) for advanced cancer of the larynx/hypopharynx
11. Prognostic significance of residual mass at the end of therapy in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS) IV experience
12. Intensity-modulated radiation therapy (IMRT) for advanced oropharyngeal carcinoma: The MSKCC experience
13. FDG-PET for staging of rhabdomyosarcoma
14. Intensity modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience
15. Radiation therapy for Ewing’s sarcoma
16. Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): Updated results of a novel combined modality paradigm
17. Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16–21 years of age with Hodgkin’s disease (HD): The Children’s Cancer Group (CCG) Experience
18. Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
19. Long term complications from treatment in survivors of high risk neuroblastoma
20. Second cancers following pediatric Hodgkin's disease.
21. Therapy for pediatric brain tumors and the risk of growth hormone deficiency.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.